I'm looking forward to them speaking at the JP Morgan Healthcare Conference next week, could be important visibility leading to new institutional buyers. https://esperion.gcs-web.com/news-r...t-39th-annual-jp-morgan-healthcare-conference
Reposting this from user stocksarelit from Stocktwits $ESPR _______________________________________ Too many signs here signaling upcoming BO or news. No recent insider buys at these cheap levels although CEO was buying big in the 40’s. Massive institutional short interest despite terrible risk/reward and hard to borrow status. Stock has been held down to current levels for months. Weird subordinated notes offering covers the majority of the short float, which would save the short ~$185M in the event of a buyout. ROW deal completion in Q4 has been anticipated for months. The date came and went with no press release or update to investors, other than an email from IR to Gary stating that deal was not completed due to an “increased interest in Bempedoic Acid abroad”??? Spectacular P2 results released showed 60% reduction in cholesterol levels when used in low-dose combination therapy. Company remains silent. What a blessing it would be if BO is announced next week. If not, I will be loading up on Mar/Jun/Jan 22 calls in anticipation for the big day.
